Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Operating Expenses (2016 - 2026)

Cumberland Pharmaceuticals' Operating Expenses history spans 16 years, with the latest figure at $15.0 million for Q4 2025.

  • On a quarterly basis, Operating Expenses rose 22.58% to $15.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $47.3 million, a 6.8% increase, with the full-year FY2025 number at $47.3 million, up 6.8% from a year prior.
  • Operating Expenses hit $15.0 million in Q4 2025 for Cumberland Pharmaceuticals, up from $10.3 million in the prior quarter.
  • Over the last five years, Operating Expenses for CPIX hit a ceiling of $15.5 million in Q4 2023 and a floor of $9.6 million in Q3 2021.
  • Historically, Operating Expenses has averaged $11.6 million across 5 years, with a median of $11.1 million in 2022.
  • Biggest five-year swings in Operating Expenses: soared 36.23% in 2023 and later dropped 20.95% in 2024.
  • Tracing CPIX's Operating Expenses over 5 years: stood at $12.7 million in 2021, then fell by 10.04% to $11.4 million in 2022, then skyrocketed by 36.23% to $15.5 million in 2023, then dropped by 20.95% to $12.3 million in 2024, then increased by 22.58% to $15.0 million in 2025.
  • Business Quant data shows Operating Expenses for CPIX at $15.0 million in Q4 2025, $10.3 million in Q3 2025, and $11.6 million in Q2 2025.